Nebkliq (Amlodipine Besilate, Nebivolol Hydrochloride)

• Nebkliq is an antihypertensive medication that acts on vascular smooth muscle and cardiac beta‑1 receptors to lower blood pressure.
• Hypertension: reduces systolic and diastolic blood pressure, helping to prevent cardiovascular complications.

• Amlodipine besilate inhibits L‑type calcium channels in vascular smooth muscle, causing vasodilation and decreased peripheral resistance. Nebivolol hydrochloride selectively blocks β1‑adrenergic receptors, lowering heart rate and cardiac output, while also stimulating endothelial nitric‑oxide release, further contributing to vascular relaxation and blood pressure reduction.

Nebkliq may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Dizziness: sensation of light‑headedness, especially after standing.
• Headache: mild to moderate intensity.
• Flushing: warmth and redness of the skin.
• Peripheral edema: swelling of ankles or feet.
• Fatigue: general tiredness.
• Nausea: mild stomach upset.

Serious or Rare Side Effects

• Severe hypotension: markedly low blood pressure requiring medical attention.
• Bradycardia: unusually slow heart rate.
• Heart block: impaired electrical conduction of the heart.
• Angioedema: swelling of face, lips, tongue or throat.
• Hepatic dysfunction: abnormal liver enzyme elevations.
• Allergic reactions: rash, itching, or anaphylaxis.

Before initiating therapy, clinicians should consider several safety aspects.

• Blood pressure monitoring: check regularly to avoid excessive lowering.
• Cardiac assessment: evaluate heart rate and rhythm, especially in patients with conduction disorders.
• Concomitant drugs review: assess for additive hypotensive or bradycardic agents.
• Hepatic impairment: use with caution; dose adjustment may be needed.
• Renal impairment: monitor renal function and adjust dose if required.
• Store at room temperature: keep in the original pack, protect from moisture.

Nebkliq can interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations.
• Other potent antihypertensives (e.g., ACE inhibitors, ARBs): risk of excessive blood pressure drop.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): additive cardiac effects.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce drug levels.

• Diuretics: may enhance hypotensive effect.
• Antidiabetic agents: blood glucose may be affected by blood pressure changes.